Krystal Biotech/$KRYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Krystal Biotech
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Ticker
$KRYS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
275
ISIN
US5011471027
Website
Krystal Biotech Metrics
BasicAdvanced
$4.1B
34.29
$4.16
0.78
-
Price and volume
Market cap
$4.1B
Beta
0.78
52-week high
$219.34
52-week low
$122.80
Average daily volume
387K
Financial strength
Current ratio
9.647
Quick ratio
9.059
Long term debt to equity
0.843
Total debt to equity
0.981
Profitability
EBITDA (TTM)
135.908
Gross margin (TTM)
93.20%
Net profit margin (TTM)
37.18%
Operating margin (TTM)
40.05%
Effective tax rate (TTM)
10.19%
Revenue per employee (TTM)
$1,210,000
Management effectiveness
Return on assets (TTM)
8.66%
Return on equity (TTM)
13.90%
Valuation
Price to earnings (TTM)
34.292
Price to revenue (TTM)
12.274
Price to book
4.18
Price to tangible book (TTM)
4.18
Price to free cash flow (TTM)
31.65
Free cash flow yield (TTM)
3.16%
Free cash flow per share (TTM)
450.24%
Growth
Revenue change (TTM)
247.53%
Earnings per share change (TTM)
109.01%
3-year earnings per share growth (CAGR)
-2.46%
What the Analysts think about Krystal Biotech
Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Bulls say / Bears say
Krystal Biotech's revenue surged 473% to $290.5 million in Q4 2024, with VYJUVEK achieving a 95% margin, indicating strong product performance and profitability. (stocktitan.net)
Jefferies Financial Group initiated coverage on Krystal Biotech with a 'buy' rating and a $245.00 price target, reflecting confidence in the company's growth prospects. (etfdailynews.com)
Jeune Aesthetics, a subsidiary of Krystal Biotech, announced positive interim results from the Phase 1 PEARL-1 study for KB301, showing significant improvement in wrinkles, which could expand the company's product portfolio. (stocktitan.net)
In Q1 2025, Krystal Biotech reported earnings of $1.20 per share, missing the consensus estimate of $1.38, and revenues of $88.18 million, below the expected $98.17 million, indicating potential financial challenges. (nasdaq.com)
Insider selling activity, including the sale of 25,000 shares by insider Suma Krishnan at an average price of $164.78, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
Krystal Biotech's stock entered oversold territory with an RSI reading of 29.9, suggesting potential downward pressure on the stock price. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Krystal Biotech Financial Performance
Revenues and expenses
Krystal Biotech Earnings Performance
Company profitability
Krystal Biotech News
AllArticlesVideos
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
GlobeNewsWire·3 days ago
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore
MarketBeat·1 month ago
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Krystal Biotech stock?
Krystal Biotech (KRYS) has a market cap of $4.1B as of June 27, 2025.
What is the P/E ratio for Krystal Biotech stock?
The price to earnings (P/E) ratio for Krystal Biotech (KRYS) stock is 34.29 as of June 27, 2025.
Does Krystal Biotech stock pay dividends?
No, Krystal Biotech (KRYS) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Krystal Biotech dividend payment date?
Krystal Biotech (KRYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Krystal Biotech?
Krystal Biotech (KRYS) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.